VALIANTORGNSEValiant Organics LimitedLowNeutral
Announced Sat, 16 May · 17:46 IST

Valiant Organics Limited has informed the Exchange regarding Outcome of Board Meeting held on May 16, 2026 w.r.t. re-appointment of Internal and Cost Auditor

Management Changes View source PDF

VALIANTORG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.5%1-day move
₹295.50
prior close
₹310.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.9+2.6+3.0-1.1+1.5-1.2+0.2-3.2-1.7+2.3-4.2+4.6-9.5
Up moveDown movePending
AI summary

Valiant Organics reported strong FY26 results with standalone net profit of Rs. 3,435.56 lakhs, turning around from a loss of Rs. 299.84 lakhs in FY25. Revenue from operations grew 2.7% to Rs. 73,838.31 lakhs. The company identified Pharma Business as a new reportable segment alongside Specialty Chemicals, with Pharma revenue rising 28% to Rs. 16,356.38 lakhs. The Board re-appointed Ketki D. Visariya as Cost Auditor and M/s. Manish Modi & Associates as Internal Auditor for FY26-27. Statutory auditors M/s. Gokhale & Sathe issued an un-modified opinion. The company also received Rs. 852.76 lakhs as fire insurance settlement for a 2022-23 incident, with Rs. 572.08 lakhs recognized as exceptional income.

Likely market impact

Strong turnaround in profitability and expansion into pharma segment are positive signals for investors. The company's ability to return to profit from a loss position and diversify into pharma indicates improving business fundamentals.